Anabond Stedman Pharma Research Private Limited, a active private limited company, was established on 09 November 2004 in Chennai, Tamil Nadu, India. Engaging in drug formulation & development within the pharma sector, it holds CIN: U33112TN2004PTC054628. Registered under ROC Roc Chennai. it is unlisted. It has an authorized capital of ₹1.00 Cr and a paid-up capital of ₹8.95 M.
It upholds a compliant status. Its leadership includes Ramkumar Rajagopal (Director), Abraham Mathew Sankarathil (Director), Rajagopal Rangachari (Director). Past directors included Esakiapillai Srinivasan, Abraham Mathew Sankarathil, Janakiraman Vijayakumar. It holds no open charges and ₹4.50 M settled loans. Its latest AGM occurred on 28 September 2024, with the balance sheet filed on 31 March 2024. It is based at Plot No.14A, Nehru Nagar Third Cross Street, Kottivakkam, Chennai, Tamil Nadu, 600041.
U33112TN2004PTC054628
054628
09 November 2004
₹1.00 Cr
₹8.95 M
Roc Chennai
Unlisted
Active
Explore comprehensive insights into Anabond Stedman Pharma Research Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Ramkumar Rajagopal | Director | 09 Nov 2004 | Current |
| Abraham Mathew Sankarathil | Director | 16 Dec 2020 | Current |
| Rajagopal Rangachari | Director | 09 Nov 2004 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Director | 10 Sep 2018 | Past |
| Pramod Abcsdd | Additional Director | 27 Dec 2020 | Past |
| Pramod Abcsdd | Director | 30 Sep 2020 | Past |
| Pramod Abcsdd | Additional Director | 29 Sep 2018 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Anabond Stedman Pharma Research Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 46.41% increase. The company also saw a substantial improvement in profitability, with a 251.75% increase in profit. The company's net worth moved up by a moderate rise of 7.99%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2018, Anabond Stedman Pharma Research had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
₹0
₹4,500,000.00
| Date | Lender | Amount | Status |
|---|---|---|---|
| 28 Apr 2005 | Hdfc Bank Ltd. | ₹4.50 M | Satisfied |
Explore comprehensive loan charge details -
Unlock and access historical data on people associated with Anabond Stedman Pharma Research, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Gain comprehensive insights into the Deals and Valuation data of Anabond Stedman Pharma Research, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Anabond Stedman Pharma Research's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
The activity Anabond Stedman Pharma Research Private Limited last Annual general meeting of members was held on 28 Sep 2024 as per latest MCA records. was completed.
A charge registered on 28 Apr 2005 via Charge ID 90288135 with Hdfc Bank Ltd. was fully satisfied on 17 Aug 2024. was recorded as a recent event.
The activity Anabond Stedman Pharma Research Private Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Chennai. was completed.
Progress on Abraham Mathew Sankarathil was appointed as a Director was appointed as a Director on 16 Dec 2020 & has been associated with this company since 4 years 11 months . was documented.
Progress on A charge with Hdfc Bank Ltd. amounted to Rs. 0.45 Cr with Charge ID 90288135 was registered on 28 Apr 2005. was documented.
The activity Ramkumar Rajagopal was appointed as a Director was appointed as a Director on 09 Nov 2004 & has been associated with this company since 21 years 21 days . was completed.
The CIN of Anabond Stedman Pharma Research Private Limited is U33112TN2004PTC054628.
Anabond Stedman Pharma Research Private Limited is headquartered at Plot No.14A, Nehru Nagar Third Cross Street, Kottivakkam, Chennai, Tamil Nadu, 600041.
Anabond Stedman Pharma Research Private Limited was incorporated on 09 November 2004.
The current directors of Anabond Stedman Pharma Research Private Limited are
The primary industry of Anabond Stedman Pharma Research Private Limited is Pharma.
Anabond Stedman Pharma Research Private Limited is unlisted.
The authorized capital of Anabond Stedman Pharma Research Private Limited is ₹1.00 Cr, and the paid-up capital is ₹8.95 M.
The compliance status of Anabond Stedman Pharma Research Private Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX